David Wambeke Acquires 1,000,000 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke acquired 1,000,000 shares of the company’s stock in a transaction that occurred on Sunday, March 1st. The shares were acquired at an average cost of $0.67 per share, with a total value of $670,000.00. Following the purchase, the insider directly owned 1,000,000 shares of the company’s stock, valued at $670,000. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

NeuroOne Medical Technologies Stock Down 2.5%

NASDAQ:NMTC opened at $0.79 on Thursday. The stock has a market cap of $39.92 million, a P/E ratio of -4.65 and a beta of 0.74. The business’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $0.79. NeuroOne Medical Technologies Corporation has a twelve month low of $0.40 and a twelve month high of $1.16.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of NMTC. Sio Capital Management LLC bought a new position in NeuroOne Medical Technologies during the 2nd quarter worth approximately $2,390,000. Vanguard Group Inc. boosted its stake in shares of NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares during the period. Renaissance Technologies LLC grew its holdings in shares of NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in shares of NeuroOne Medical Technologies in the fourth quarter worth approximately $143,000. Finally, Virtu Financial LLC purchased a new position in shares of NeuroOne Medical Technologies in the third quarter worth $88,000. Institutional investors own 16.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NMTC. JonesTrading began coverage on shares of NeuroOne Medical Technologies in a research report on Monday. They set a “buy” rating and a $1.50 price objective on the stock. Zacks Research upgraded NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1.98.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.